Immunization against AIDS in humans

Zagury, Daniel; Leonard, Reid J.; Fouchard, M; Réveil, Brigitte; Bernard, Jacky; Ittelé, D.; Cattan, A.; Zirimwabagabo, Lurhuma; Kalumbu, Mbayo; Justin, Wane; Salaun, J.J.; Goussard, B.

doi:10.1038/326249a0

Cited by 95 publications

(31 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Although the immune mechanisms needed for protection against HIV have not yet been identified, delaying efficacy trials until protective mechanisms have been clearly elucidated is not warranted, because these mechanisms may not be defined for many years. This study, as well as others evaluating potential HIV vaccine candidates (47,(67)(68)(69)(70), have established the feasibility of proceeding to randomized trials, and definitive establishment of efficacy will ultimately be provided only by such a trial. …”

Section: Discussionmentioning

confidence: 99%

Induction of humoral and cell-mediated anti-human immunodeficiency virus (HIV) responses in HIV sero-negative volunteers by immunization with recombinant gp160.

Kovacs

Vasudevachari²,

Easter³

et al. 1993

J. Clin. Invest.

View full text Add to dashboard Cite

Development of an effective vaccine for prevention of infection with HIV would provide an important mechanism for controlling the AIDS epidemic. In the current study, the first clinical trial of a candidate HIV-1 vaccine initiated in the United States, the safety and immunogenicity of escalating doses (10-1,280 Aig) of recombinant gp160 (rgpl6O), were evaluated in 138 HIV-negative volunteers. Maximal antibody responses, as evaluated by ELISA, were seen after immunization with three doses of 1,280 ;&g rgpl6O. Responses to some specific epitopes of HIV gp160, including the second conserved domain and the CD4 binding site, were seen more frequently than after natural infection. Neutralizing antibodies to the homologous HIV strain, but not heterologous strains, were induced by this regimen. Blastogenic responses to rgpl60 were seen in most volunteers receiving at least two doses of 2 20 Mg. These envelopespecific T cell responses were also seen against heterologous strains of HIV. No major adverse reactions were seen after immunization. Thus, rgpl60 is a safe and immunogenic candidate HIV vaccine; further studies are needed to determine if it will provide any clinical benefit in preventing HIV infection. (J. Clin. Invest. 1993. 92:919-928.)

show abstract

Section: Discussionmentioning

confidence: 99%

Induction of humoral and cell-mediated anti-human immunodeficiency virus (HIV) responses in HIV sero-negative volunteers by immunization with recombinant gp160.

Kovacs

Vasudevachari²,

Easter³

et al. 1993

J. Clin. Invest.

View full text Add to dashboard Cite

show abstract

“…viruses have been developed and tested in non-human primates (25)(26)(27)(28)(29) and humans (30). Chimpanzees vaccinated with vaccinia-HIV demonstrate very low titers of neutralizing antibodies (25).…”

Section: Bmentioning

confidence: 99%

“…Filters were washed under high stringent conditions (2X SSC, 0.1% SDS) for 3 hours at 650C and autoradiographed (30,37).…”

Section: Southern Blotmentioning

confidence: 99%

Development and Evaluation of Adeno-HTLV-III Hybrid Virus and Non- Cytopathic HTLV-III Mutant for Vaccine Use

Lubet¹,

Dusing²

1988

View full text Add to dashboard Cite

“…MoAbDZ was obtained from B lymphocytes of an individual immunized with recombinant vaccinia virus (VSC-25) expressing HIV-1 gpl60 env protein (Chakrabarti et al, 1986;Zagury et al, 1987Zagury et al, , 1988 and MoAbC31, from B lymphoeytes of an asymptomatic donor.…”

Section: Discusstonmentioning

confidence: 99%

Characterization and large production of human monoclonal antibodies against the HIV-1 envelope

Boyer

Broly

Souche

et al. 1991

Clinical and Experimental Immunology

View full text Add to dashboard Cite

SUMMARYPeripheral blood lymphocytes from a volunteer immunized with a reeombinant vaccinia virus VSC-25 expressing the gpl60 env protein of HTLV-IIIB strain and from an asymptomatic HIV-infected individual were immortalized by Epstein-Barr (EBV). Clones which secrete human monoclonal antibodies from the two individuals (DZ, IgGl, I and C3!, IgGl, K) were obtained and were stable for more than 2 years. The two monoclonals were directed against the gp 160 env protein of HI V, DZ directed against the gp41 and C31 directed against the gpl20. C31 was group-specific, whereas DZ was directed against the HTLV-IIIB and HTLV-RF strains. The epitope recognized by DZ was mapped to the carboxy terminus of the gp41, by expression of HIV DNA fragments in a yeast system and peptide analysis. The C31 epitope was not expressed by the yeast library and not present among the peptides which were tested. Monoclonal antibodies had no inhibitory effect in an HIV-induced cell fusion assay, but DZ showed a weak neutralizing activity against the HTLV-IIIB strain. Cloned EBV-transformed cell lines were fused to a murine myeloma, which allowed the heteromyeloma to be cultivated in serum-free medium. The monoclonal antibodies were produced in large quantity in a hollow-fibre reactor at defined culture conditions and purification procedures.

show abstract

Immunization against AIDS in humans

Cited by 95 publications

References 12 publications

Induction of humoral and cell-mediated anti-human immunodeficiency virus (HIV) responses in HIV sero-negative volunteers by immunization with recombinant gp160.

Induction of humoral and cell-mediated anti-human immunodeficiency virus (HIV) responses in HIV sero-negative volunteers by immunization with recombinant gp160.

Development and Evaluation of Adeno-HTLV-III Hybrid Virus and Non- Cytopathic HTLV-III Mutant for Vaccine Use

Characterization and large production of human monoclonal antibodies against the HIV-1 envelope

Contact Info

Product

Resources

About